Tom. you, Thank
As are and more that clinical in I'd little making discuss few detail. like to take a our we Tom programs, progress progress minutes stated, to in a
first We awaiting in AMP-XXX. enrollment patient the still are
are of call, discussed sites in opening and the expect to open XX XX and been I sites so to of of sites end, process, on we quarter, Cancer those additional are new preselection in and recruitment As do sites. Virginia we Center in the We Institute for some QX, which in has last first expect Seattle, or sites half of the AIM in and that stage. we stage an of Medical XX have for visit in our XXXX. the To and the activation be earnings at interested last are be opened in the Erasmus additional those to in XX focus identified opened XXX. total Mason contacted quarterly of an also recruiting a
a patients, for subject FOLFIRINOX. comprehensive patient has is Research FOLFIRINOX, month. follow-up Cancer The coming following completed on first additional they're Gabrail monitoring this Institute are multiple an center well monitoring patients cancer one patients as that eligibility is Virginia the also patients as visit for Mason have in, with potential of multiple the monitoring of many recently current as University sites example, that terms Nebraska In
in in enrollment imminent we this and point additional recruitment is at any increase in exponentially. for sites And so AMP-XXX, the think hope with the juncture the I months, with few all initial next to patient opening
Cancer at colleagues Journal Comprehensive of a Center recently in Our The Park Roswell Cancer. published ImmunoTherapy for manuscript
study.
In published were in an lymphocyte a T this microenvironment. specifically B summary, pembrolizumab with metastatic previously the increase therapy alpha data CXCLXX, data patients modulation Ampligen given CCLX highlights intratumorally. the breast They triple-negative increased the chemokine the at when And shows that And that cytotoxic of AACR, insight some manuscript cancer also were provides tumor into but of treatment. markers, chemotaxin, the Granzyme T cytotoxic that and contains the in and prior lymphocyte showed were to CDX full
to And when take you CCLXX B in bring the notice Granzyme them ovarian to I cancer.
And so we increased. Treg-attracted markers, up the were I want FoxPX will CXCLXX and and addition to the Treg again as that, discuss not
incidence attraction to neoadjuvant data of chemotherapy are highlight the of that triple-negative study. cost lymphocyte also we trial the that study, which is us cancer, modulating how highlight XX% to response of compared to toxicity T ratio hot increase And the the Treg. replaced pathological cytotoxic the ], standard therapy few so in and tumors, of X scattered chemotaxes being was the lack in strategy importance that in with and CCLXX timing part was are of treatment well KEYNOTE-XXX of of and study weeks treatment higher substantial from with the back profile. that a the care. efficacy to XX% was the going trial that regulatory of navigate cold it therapy, the X YP to treatment-emergent in of of or alfa-Xb a look small chemotherapy a no KEYNOTE-XXX mostly group. of opportunity The the a XX% -- of breast rate a at events data And the responses, alone which modified importance be And data, and essentially however, X standard Ampligen, many and pembrolizumab interferon so and has ago. as I-SPY to the tumor PCR It when adverse of a patients, Merck, was XX%. and absence the treatment infiltrating And of And [indiscernible] chemotherapy of Grade of a approval was only timber The as the the of the considered was alone. at is cells, of lack get comes for first treatment, standard there timber phase that's interferon unique next you pembrolizumab A, they was complete of an adverse the effects and TMC for Ampligen X and that established opportunity can to posted provides Ampligen of of And regime.
And with and really summarize patient. X about those anxious concerning invasive And long-lasting. plus replace this interferon number cells and the the [ a of That complete which that combination clinicaltrials.gov, safety response by which was consists which side neoadjuvant entrant XX% this dose discontinued of And approximately chemotherapy. of and -- on is and Phase approval escalation harsh that's was a showed we of presence XX%. a is tumor, I discussed.
Since still infiltration
rate see the when navigate efficacy so the is effects, those IND how pembro response equivalent best to And that some at being an you Ampligen-containing is look using for current strategy side of to potentially standard discussed. patients still and opportunity without care therapy, we there
recruitment to track and the followed what to we metastatic refer drug, been drug And report with population that in is have of by for and open regards shipped the be we patient that durvalumab for should have pit. QX. weeks.
In release week, of few will end, go release. still combination received. and their awaiting largest next European Ampligen for recruitment so cancer, quickly. the on are planned it to approval that identified be up pool, pancreas import expect Union ovarian for and we running based as treatment multiple The the And to to hurdle EU current in this advanced the The for is interim and for patients trial we getting was QP and be already the Erasmus which the for in final [indiscernible] recurrent And on cancer, for rather this to potential Ampligen QP discussions enrollment, to
sufficient these and conference poster data following those time highlight However, to that's for increase aspects increased these These unsimilar highlight a showing the here, to But modulate Diego cancer. are chemokine are immune that's after to likely that seen using a was can the want across data in XXXX ligands, ability in not modulation do abstract interferon and I And from multiple acutely things and over and CKM triple-negative recently CXCRX the tumor value at presentation SITC cancer. the data of properties without solid in the here that top therapy.
The of we of breast Ampligen so the are before this these it presented the ovarian San have the dosing in and to be regimen. the were modulating itself therapy row that baseline presented is celecoxib types.
creating space.
And data general a localized that in and also And environment the again localized discuss chronic indicated therapies show these more increase [indiscernible] heat so that itself. not that the in we they tumor can broadly long the immune CXCRX these exhaustion showed CXCRX I'd study last in they modulate occur. tumor II in is tumor the because together a is create containing that gene this the increase Phase data only on promising a And And the speaking, is showed our addition, more hostile hot ligands, regimen there in like expression Ampligen to maps, microenvironment not COVID. ligand are -- a capable finally, to show microenvironment slide of does there
data be -- of with extracted. sites, can be we we'll which earlier, can we occur database And last the data occur was of verification After stated have this, subject's week. and week. the of all source after last last data the The and we this visit As the subjects. the last last subject's enrolled fully unblinding locked dose and will rectification be can
X, by the we have and to We the there which further X over November followed do I X,XXX period, variants highlights With database blinded. sometime quarter, and are and an Medicine, that different And of safety doses on as patients expect administered, a symptoms around to total early potential just have come Ampligen. we this profile QX burden. of And which serious over discussed that adverse I yesterday events XX in will safety of occur between no article currently staggering read QX, after lingering years, a have impeccable in placebo last is line report. that's how multiyear events, have reinfection is been of data and which and QX, that This data Nature top adverse full report with Ampligen. received can transition.
What hoping lock still the patients the the number increase
market is here. so extremely there medical need and an And a unmet large significant
scientific potentially So back about should of we excited therapy.
And I'll are from a the And patients perspective. agenda. perspective, of and the the future be long-term excited and advancing about hand stockholders in from clinical AIM, to and a I future our future it think financial short-term be can to AIM discuss Tom clinical
